The challenges of treating early-stage TNBC
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
What to do in patients with early-stage TNBC who have not achieved a pCR?
FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage ...
Emerging immunotherapy beyond checkpoint inhibitors for TNBC
Immunotherapy Keytruda Shows Benefit in Early Triple-Negative Breast Cancer
De-escalation of therapy in early-stage TNBC
KEYNOTE-355: pembrolizumab in triple-negative breast cancer
KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC
New directions in immunotherapy for improving outcomes in TNBC
Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
Results for Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Tripl...
GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."
First immunotherapy success for triple-negative breast cancer
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC
Dr. Nanda On Pembrolizumab Potential for TNBC
Keytruda Immunotherapy for Triple Negative Breast Cancer
2022 West Oncology Conference | Breast Cancers | Early-Stage
